Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGAIN trial of abemaciclib rechallenge in ER-positive HER2-negative metastatic breast cancer
jRCTs031210129Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of abemaciclib in breast cancer, sponsored by Eli Lilly and Company. Primary endpoint: Progression-free survival. Started Jun 2021; status: active, not recruiting.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCTs031210129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031210129.